Back To Search Instructions
Protocols
31 protocol(s) meet the specified criteria
PI: Gold, Stuart
Protocol No.TitleStatus
ACCL1333A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-AsparaginaseOpen
CC-5013-AML-002A Phase 2, Multicenter, Single-Arm, Openlabel Study to Evaluate the Activity, Safety and Pharmacokinetics Of Lenalidomide (Revlimid®) In Pediatric Subjects from 1 To ≤ 18 Years Of Age With Relapsed or Refractory Acute Myeloid Leukemia Open
COG-AALL0331Standard Risk B-precursor Acute Lymphoblastic LeukemiaOpen
COG-AALL05B1A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research SpecimensOpen
COG-AALL08B1Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Open
COG-AALL0932Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)Open
COG-AALL1231A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)Open
COG-AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
COG-AAML1531Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeOpen
COG-ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
COG-ACNS0831Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 yearsOpen
COG-ACNS1123Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)Open
COG-AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaOpen
COG-AHEP0731Treatment of Children with All Stages of HepatoblastomaOpen
COG-AHOD1331A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and AdolescentsOpen
COG-ANBL1221A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive NeuroblastomaOpen
COG-ANBL1232Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaOpen
COG-ANHL12P1A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117Open
COG-AOST06B1A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma SpecimensOpen
COG-AOST1321Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory OsteosarcomaOpen
COG-APEC14B1 The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Open
COG-ARST1321Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)Open
COGAALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
COGAAML08B1Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)Open
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
COGACNS0332Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Open
COGAEWS1031A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing SarcomaOpen
COGAREN03B2Renal Tumors Classification, Biology, and Banking Study Open
INCB-8424-269A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic LeukemiaOpen
MIBG-EXPANDED-ACCESSAn Open Label, Expanded Access Protocol Using 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy In Patients With Refractory Neuroblastoma, Pheochromocytoma, Or ParagangliomaOpen
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen